IN
INDP
Methodology breakdown computing — it will appear here on its own.
Indaptus Therapeutics Inc. (INDP) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-25). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for INDP — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 76.90 | SELL |
| Stochastic %K (14) | 83.24 | SELL |
| CCI (20) | 255.26 | SELL |
| Williams %R (14) | -16.76 | SELL |
| MACD (12,26,9) | 0.21 | BUY |
| ROC (10) | 126.29 | BUY |
| Momentum (10) | 1.47 | BUY |
| EMA (10) | 1.82 | BUY |
| SMA (10) | 1.61 | BUY |
| EMA (20) | 1.60 | BUY |
| SMA (20) | 1.36 | BUY |
| EMA (30) | 1.61 | BUY |
| SMA (30) | 1.31 | BUY |
| EMA (50) | 1.74 | BUY |
| SMA (50) | 1.77 | BUY |
| EMA (100) | 1.99 | BUY |
| SMA (100) | 2.18 | BUY |
| EMA (200) | 2.21 | BUY |
| SMA (200) | 2.19 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Indaptus Therapeutics Inc.
Healthcare · Biotechnology
Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Background via Yahoo Finance — informational, not part of the verdict.
🟡 BULLISH LEAN
The main driver: outperforming the market by 155.4%, Wall Street broadly bullish. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert INDP [level]` to catch the entry, or `!plan INDP` to size small.
Scores: 3 bullish / 1 bearish
Good setup, solid confluence
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 62 |
| ⏰ 4H | BULLISH | 37 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.